DiObex Inc. to Present at BIO Mid-America Venture Forum

Wednesday, September 19, 2007 General News J E 4
SAN FRANCISCO, Sept. 18 DiObex, Inc., a privately heldbiotechnology company focused on the development of therapeutics to treatmetabolic diseases, announced today that CEO David Cory will deliver acorporate presentation at the upcoming Biotechnology Industry Organization(BIO) Mid-America Venture Forum in Milwaukee, Wisconsin. The DiObexpresentation will take place on Wednesday, September 26th at 1:30 p.m. at theHyatt Regency Hotel in Room A.

About DiObex

DiObex, Inc. is a San Francisco-based biotechnology company founded todevelop novel products for the treatment of metabolic diseases. DiObex hastwo product candidates in Phase 2 clinical development. DIO-901 (very lowdose glucagon) is in development as an extended release subcutaneousformulation for reducing or preventing insulin-induced hypoglycemia in type 1diabetes mellitus. DIO-901 has received Fast Track status from the Food andDrug Administration. DIO-902 (levdexketoconazole) is a novel cortisolsynthesis inhibitor in development for type 2 diabetes mellitus.Abnormalities in cortisol activity may play an important role in thedevelopment of metabolic syndrome, a constellation of conditions that placepeople at high risk for type 2 diabetes mellitus and cardiovascular disease.For more information, visit

SOURCE DiObex, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Cor...
U. of Md. Researchers to Develop Devices to Revolu...